Breast Cancer,HER2- Safety Analysis of Palbociclib with Fulvestrant/Letrozole in HR+/HER2- ABC: PARSIFAL Trial Mar 14, 2023
Breast Cancer,TNBC (Triple Negative Breast Cancer) Adjuvant Olaparib Improves OS in High-Risk EBC: OlympiA Phase III Mar 09, 2023
Breast Cancer,TNBC (Triple Negative Breast Cancer) A Phase 3 ASCENT Study on Sacituzumab Govitecan in mTNBC and HRQoL Mar 09, 2023
Breast Cancer,HER2- A Phase 3 Study Analyzing PBO+ET in Advanced HR+ Breast Cancer Subgroups Mar 07, 2023
Breast Cancer,HER2- Capivasertib and Faslodex Combo Outperform Faslodex for Advanced Breast Cancer Mar 06, 2023
Breast Cancer,HER2- Abemaciclib Plus Endocrine Therapy in Premenopausal HR+, HER2- EBC: MonarchE Study Mar 03, 2023
